Newly identified oncolytic VSV-GP-specific CD8⁺ T cell epitopes for monitoring of anti-viral immune responses in the BALB/c mouse model.

ABSTRACT: The vesicular stomatitis virus variant VSV-GP is an oncolytic virus (OV) platform extensively studied in preclinical settings, which recently entered clinical trial testing. For oncolytic virotherapy, innate and adaptive immune system activation are considered major contributors. However, upon OV treatment, in addition to potential anti-tumor, anti-viral T cells are also raised, and comprehensively monitoring these anti-viral T cells presents a major challenge. Therefore, we aimed to identify anti-viral CD8⁺ T cells upon VSV-GP treatment in the widely utilized BALB/c mouse model using a multi-level adapted bioinformatics viral epitope prediction approach. Predicted viral epitopes presented on BALB/c major histocompatibility complex class I (MHC-I) alleles H2-Kd, H2-Dd, and H2-Ld

SUBMITTER: Danklmaier S 

PROVIDER: S-EPMC12634848 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature